$2.67 EPS Expected for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) This Quarter

Equities research analysts expect that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will announce earnings of $2.67 per share for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. Regeneron Pharmaceuticals posted earnings of $2.11 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.5%. The firm is scheduled to report its next earnings report before the market opens on Thursday, August 3rd.

On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $10.52 per share for the current year, with EPS estimates ranging from $10.33 to $10.71. For the next year, analysts anticipate that the firm will post earnings of $12.10 per share, with EPS estimates ranging from $11.57 to $12.62. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. Regeneron Pharmaceuticals’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business earned $2.57 EPS.

A number of analysts have recently issued reports on REGN shares. BMO Capital Markets reissued a “hold” rating and set a $412.00 target price (up from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 28th. Leerink Swann reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, March 20th. Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $375.00 to $484.00 in a research note on Friday, May 5th. Vetr lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 price objective for the company. in a research note on Monday, May 1st. Finally, Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective for the company in a research note on Thursday, April 27th. One analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $457.83.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/08/10/2-67-eps-expected-for-regeneron-pharmaceuticals-inc-nasdaqregn-this-quarter-updated-updated-updated.html.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded down 0.03% on Monday, hitting $504.90. 608,260 shares of the company traded hands. The firm’s 50-day moving average is $474.83 and its 200 day moving average is $400.97. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a market capitalization of $53.30 billion, a P/E ratio of 61.12 and a beta of 1.67.

In related news, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the director now owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the sale, the executive vice president now owns 43,950 shares in the company, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of REGN. Thrivent Financial for Lutherans raised its stake in shares of Regeneron Pharmaceuticals by 6.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,620 shares of the biopharmaceutical company’s stock worth $962,000 after buying an additional 160 shares in the last quarter. RMB Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 5.4% in the fourth quarter. RMB Capital Management LLC now owns 5,818 shares of the biopharmaceutical company’s stock worth $2,136,000 after buying an additional 300 shares in the last quarter. Perigon Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 23.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,289 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 248 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.0% in the fourth quarter. Teachers Advisors LLC now owns 93,990 shares of the biopharmaceutical company’s stock worth $34,503,000 after buying an additional 5,295 shares in the last quarter. Finally, Kentucky Retirement Systems purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $2,014,000. Hedge funds and other institutional investors own 66.90% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply